RxDoctor Payments Data

Akram Dera

Hospitalist · Hattiesburg, MSNPI 1316346968

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.5% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.

$805in general payments, 2019–2025

Across 43 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$165
  • E.r. Squibb & Sons, L.L.C.$147
  • Boehringer Ingelheim$118
  • Johnson & Johnson$111
  • AstraZeneca$104
  • Pfizer$102
  • plus $58 from 2 others

What the payments were for

  • Food & beverage$74593%
  • Education$607%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$805 in reported general payments places this provider in the 60th percentile of 102 hospitalist providers in Mississippi.

See all hospitalist providers in Mississippi

Medicare billing

Part B allowed, 2024
$110,332
Medicare patients
393
Services billed
1,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$35,528
JardianceEmpagliflozin16$8,824
Levetiracetam28$511
Pantoprazole Sodium64$412
Metoprolol Succinate34$351
Amiodarone Hcl53$264
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav37$257
Metronidazole15$179
Furosemide71$178
ClopidogrelClopidogrel Bisulfate37$172
Tamsulosin Hcl15$146
Amlodipine Besylate36$118
Doxycycline Monohydrate20$109
Carvedilol23$97
Metoprolol Tartrate32$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$35,52851 claims
Boehringer IngelheimJardiance$118$8,82416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 102 hospitalist providers in Mississippi.

Other hospitalist in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →